HMGB2P1: A Potential Drug Target and Biomarker (G729119)

Target Name: HMGB2P1

NCBI ID: G729119

HMGB2P1

Other Name(s): high mobility group box 2 pseudogene 1 | High mobility group box 2 pseudogene 1

HMGB2P1: A Potential Drug Target and Biomarker

High mobility group box 2 (HMGB2) pseudogene 1 (HMGB2P1) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. HMGB2P1 is a non-coding RNA molecule that is expressed in various tissues and cells in the body. It is a key component of the high mobility group box (HMB) family of genes, which are characterized by the presence of a high-conservability cluster of putative trans-membrane proteins (HMBs) in the cytoplasm.

HMGB2P1 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and testes. It is highly expressed in the placenta, where it is a critical component of the placenta-specific transcriptome. HMGB2P1 has been shown to play a role in various physiological processes, including cell signaling, cell adhesion, and tissue repair.

Drug Target Potential
HMGB2P1 has been identified as a potential drug target due to its unique structure and its involvement in various signaling pathways. One of the key reasons for its potential as a drug target is its high mobility, which allows it to interact with various signaling molecules and drugs. Additionally, its intrinsic stability and the presence of a variable region make it a good candidate for small molecules that can inhibit its activity.

Another potential reason for HMGB2P1's drug target potential is its involvement in various signaling pathways that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, HMGB2P1 has been shown to be involved in the Wnt signaling pathway, which is involved in the development and maintenance of tissues and organs. Additionally, it has been shown to be involved in the Notch signaling pathway, which is involved in the regulation of cell growth and differentiation.

Biomarker Potential
HMGB2P1 has also been identified as a potential biomarker for various diseases. Its high expression in various tissues and its stability make it a good candidate for diagnostic applications. For example, HMGB2P1 has been shown to be highly expressed in cancer tissues and has been used as a biomarker for cancer diagnosis and monitoring. Additionally, its expression has been shown to be associated with various neurological disorders, including Alzheimer's disease and Parkinson's disease.

Another potential application of HMGB2P1 as a biomarker is its expression in skin tissues, which makes it a good candidate for skin cancer diagnosis and monitoring. Additionally, its expression has been shown to be associated with various autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Pathway Analysis
HMGB2P1 has been shown to play a role in various signaling pathways, including the Wnt, Notch, and TGF-β signaling pathways. These pathways are involved in various cellular processes, including cell signaling, cell adhesion, and tissue repair.

The Wnt signaling pathway is involved in the development and maintenance of tissues and organs. It is a complex signaling pathway that involves the interaction of various proteins, including Wnt-1, Wnt-2, and Wnt-3. Wnt-1 and Wnt-2 are involved in the development of the axon and neuron, while Wnt-3 is involved in the regulation of cell growth and differentiation.

The Notch signaling pathway is involved in the regulation of cell growth and differentiation. It is a complex signaling pathway that involves the interaction of various proteins, including Notch-1, Notch-2, and Notch-3. Notch-1 and Notch-2 are involved in the regulation of

Protein Name: High Mobility Group Box 2 Pseudogene 1

The "HMGB2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGB2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets